Home » Newsletters » BioWorld Science

BioWorld Science

April 26, 2007

View Archived Issues

Recent Merck and AstraZeneca patents report new therapeutic agents for metabolic disorders

Recent patents cover therapeutic agents for inflammatory disorders

Two phase I studies of PTC-124 in healthy adults completed

FdCyd and THU studied for treatment of solid tumors

Novel camptothecin conjugate with promising efficacy and pharmacokinetic profile

Replacement of regular insulin with Oral-lyn studied in adults, adolescents

Certolizumab pegol inhibits cytokine production by monocytes

Preclinical profile of MORAb-009 reported by Morphotek

Vaccine targeting prostatic acid phosphatase tested in prostate cancer patients

Promising preclinical profile of STI-1698, a topoisomerase I inhibitor developed at Sigma-Tau

LX-1031 begins phase Ib study for IBS

Introgen initiates efficacy analyses of Advexin phase III study

NS-2359 begins second phase II study for depression

U.S. development of CollaRx Gentamicin Surgical Implant to open at phase III

Agensys discover AGS-16 as a novel target for the treatment of kidney cancer

Exelixis cleared to resume clinical testing of XL-999

Dosing completed in phase I metastatic melanoma study of Provecta

Novartis in-licenses CYT002-NicQb for treatment of nicotine addiction

New data confirm oral bioavailability of AL-309

PCK-3145 shows evidence of clinical activity in metastatic prostate cancer patients

Miraxion fails to meet endpoints in phase III Huntington's studies

Phase IIa results for i.v. cannabinor in postoperative pain

EpiCeram comparable to Cutivate in treating atopic dermatitis symptoms

Alitretinoin shows retreatment benefit in chronic hand eczema

Abbott discontinues development of levosimendan in U.S.

Singulair approved to prevent exercise-induced bronchoconstriction

Novel therapeutic agents for atherosclerosis reported in recent Merck and Merck Frosst patents

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...